ASND — Ascendis Pharma A/S
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1612042 ·
Denmark
Last close
$271.19
Market Cap
$17.84B
52W High
$282.15
52W Low
$188.08
ADV30
713,003
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 369,657,000 | 341,346,000 | 124,576,000 | 73,973,000 | 2,427,184,000 | 964,364,000 | 926,733,000 |
| Jun 2026 | 339,285,000 | 311,627,000 | 220,465,000 | 206,970,000 | 2,286,020,000 | 812,260,000 | 849,529,000 |
| Mar 2026 | 246,601,000 | 229,086,000 | 24,812,000 | 629,339,000 | 2,003,279,000 | 572,820,000 | 1,515,306,000 |
| Dec 2025 | 247,500,000 | 223,902,000 | 6,442,000 | -33,562,000 | 1,302,570,000 | 616,041,000 | 1,465,391,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$349,512,000
Investing CF
$-13,051,000
Financing CF
$-35,581,000
CapEx
$-8,485,000
Dividends Paid
—
Buybacks
$-103,412,000
EPS Diluted TTM
$11.03
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,878,483,000
Inventory
$310,576,000
Receivables
$224,102,000
ST Investments
—
EBIT TTM
$219,526,000
Pretax Income TTM
$97,839,000
Interest Exp TTM
$121,687,000
Analysts
21
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,047,020,032
EBITDA
$263,454,000
Free Cash Flow
$12,771,750
Enterprise Value
$16,943,709,184
Total Cash
$812,259,968
Total Debt
$450,073,984
Shares Out
65,783,370
Trailing EPS
$13.02
Book Value
$25.38
ROE
118.8%
ROA
9.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 720,132,000 | -136,271,000 | -228,034,000 | 1,302,570,000 | 1,465,391,000 | -162,821,000 | 53,897,000 |
| Dec 2024 | 363,641,000 | -278,763,000 | -378,084,000 | 1,179,495,000 | 1,285,201,000 | -105,706,000 | -306,197,000 |
| Dec 2023 | 266,718,000 | -455,541,000 | -481,447,000 | 825,587,000 | 971,284,000 | -145,697,000 | -467,361,000 |
| Dec 2022 | 51,174,000 | -561,814,000 | -583,194,000 | 1,089,738,000 | 826,390,000 | 263,348,000 | -495,699,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$11.22
Max Pain — expiry 2026-12-18
max pain strike: $240.00 · spot: $270.33 · call oi: 2,246 · put oi: 1,158Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JAZZ | Jazz Pharmaceuticals plc | $15.45B | $240.71 | — |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $20.96B | $156.50 | — |
| BBIO | BridgeBio Pharma, Inc. | $14.96B | $76.80 | — |
| VTRS | Viatris Inc | $23.45B | $20.45 | — |
| ELAN | Elanco Animal Health Inc | $12.92B | $25.85 | — |
News headlines (Yahoo Finance, 1h cache)
Ascendis Pharma (ASND) Could Be 12% Below Fair Value Following Q3 Earnings
2026-11-13 12:12 · Yahoo
Ascendis Pharma (ASND) Stock Looks About Right After An 18% Rise
2026-11-13 11:10 · Yahoo
Ascendis Pharma earnings analysis: questions answered and next catalysts
2026-11-12 20:55 · Yahoo
Ascendis Pharma A/S Q3 Earnings Call Highlights
2026-11-12 17:15 · Yahoo
Ascendis (ASND) Q3 2026 Earnings Call Transcript
2026-11-12 15:29 · Yahoo
Ascendis Pharma Reports Third Quarter 2026 Financial Results
2026-11-12 12:30 · Yahoo
Ascendis Pharma to Participate in the Jefferies London Healthcare Conference
2026-11-10 21:01 · Yahoo
Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
2026-11-06 13:00 · Yahoo
Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
2026-11-05 21:01 · Yahoo
TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
2026-10-26 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.